The results of the pivotal IRIS trial documented the superiority of imatinib compared to the combination of IFN +Aracytine in the treatment of newly diagnosed patients with CML in chronic phase.12 In 2013 the TKI inhibitors imatinib, nilotinib and dasatinib are approved as first line therapy in CML,13,14 while bosutinib and ponatinib are approved for use as second/third line therapy in CML.15,16. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.